Literature DB >> 30455402

Suppression of Th1 Priming by TLR2 Agonists during Cutaneous Immunization Is Mediated by Recruited CCR2+ Monocytes.

Christopher T Johndrow1, Michael F Goldberg2, Alison J Johnson1, Tony W Ng1, Shajo Kunnath-Velayudhan1, Gregoire Lauvau1, Daniel H Kaplan3,4, Graeme H Gossel5, Ulrich D Kadolsky6, Andrew J Yates7, John Chan1,8, William R Jacobs1,9, Steven A Porcelli10,8.   

Abstract

Effective subunit vaccines require the incorporation of adjuvants that stimulate cells of the innate immune system to generate protective adaptive immune responses. Pattern recognition receptor agonists are a growing class of potential adjuvants that can shape the character of the immune response to subunit vaccines by directing the polarization of CD4 T cell differentiation to various functional subsets. In the current study, we applied a high-throughput in vitro screen to assess murine CD4 T cell polarization by a panel of pattern recognition receptor agonists. This identified lipopeptides with TLR2 agonist activity as exceptional Th1-polarizing adjuvants. In vivo, we demonstrated that i.v. administration of TLR2 agonists with Ag in mice replicated the findings from in vitro screening by promoting strong Th1 polarization. In contrast, TLR2 agonists inhibited priming of Th1 responses when administered cutaneously in mice. This route-specific suppression was associated with infiltrating CCR2+ cells in the skin-draining lymph nodes and was not uniquely dependent on any of the well characterized subsets of dendritic cells known to reside in the skin. We further demonstrated that priming of CD4 T cells to generate Th1 effectors following immunization with the Mycobacterium bovis bacillus Calmette-Guérin (BCG) strain, a lipoprotein-rich bacterium recognized by TLR2, was dependent on the immunization route, with significantly greater Th1 responses with i.v. compared with intradermal administration of BCG. A more complete understanding of route-dependent TLR2 responses may be critical for informed design of novel subunit vaccines and for improvement of BCG and other vaccines based on live-attenuated organisms.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30455402      PMCID: PMC6487659          DOI: 10.4049/jimmunol.1801185

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  61 in total

1.  Toll-like receptor 2-dependent inhibition of macrophage class II MHC expression and antigen processing by 19-kDa lipoprotein of Mycobacterium tuberculosis.

Authors:  E H Noss; R K Pai; T J Sellati; J D Radolf; J Belisle; D T Golenbock; W H Boom; C V Harding
Journal:  J Immunol       Date:  2001-07-15       Impact factor: 5.422

2.  Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling.

Authors:  Katja Farhat; Sabine Riekenberg; Holger Heine; Jennifer Debarry; Roland Lang; Jörg Mages; Ute Buwitt-Beckmann; Kristina Röschmann; Günther Jung; Karl-Heinz Wiesmüller; Artur J Ulmer
Journal:  J Leukoc Biol       Date:  2007-12-03       Impact factor: 4.962

Review 3.  Ontogeny and functional specialization of dendritic cells in human and mouse.

Authors:  Muzlifah Haniffa; Matthew Collin; Florent Ginhoux
Journal:  Adv Immunol       Date:  2013       Impact factor: 3.543

4.  TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes.

Authors:  Kenshi Yamasaki; Kimberly Kanada; Daniel T Macleod; Andrew W Borkowski; Shin Morizane; Teruaki Nakatsuji; Anna L Cogen; Richard L Gallo
Journal:  J Invest Dermatol       Date:  2010-11-25       Impact factor: 8.551

5.  Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses.

Authors:  Botond Z Igyártó; Krystal Haley; Daniela Ortner; Aleh Bobr; Maryam Gerami-Nejad; Brian T Edelson; Sandra M Zurawski; Bernard Malissen; Gerard Zurawski; Judith Berman; Daniel H Kaplan
Journal:  Immunity       Date:  2011-07-21       Impact factor: 31.745

6.  Activation of toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not IL-10.

Authors:  S Thoma-Uszynski; S M Kiertscher; M T Ochoa; D A Bouis; M V Norgard; K Miyake; P J Godowski; M D Roth; R L Modlin
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

7.  Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma.

Authors:  Vanessa Redecke; Hans Häcker; Sandip K Datta; Agnes Fermin; Paula M Pitha; David H Broide; Eyal Raz
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

8.  Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells.

Authors:  Brian T Edelson; Wumesh KC; Richard Juang; Masako Kohyama; Loralyn A Benoit; Paul A Klekotka; Clara Moon; Jörn C Albring; Wataru Ise; Drew G Michael; Deepta Bhattacharya; Thaddeus S Stappenbeck; Michael J Holtzman; Sun-Sang J Sung; Theresa L Murphy; Kai Hildner; Kenneth M Murphy
Journal:  J Exp Med       Date:  2010-03-29       Impact factor: 14.307

9.  Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells.

Authors:  T L Stevens; A Bossie; V M Sanders; R Fernandez-Botran; R L Coffman; T R Mosmann; E S Vitetta
Journal:  Nature       Date:  1988-07-21       Impact factor: 49.962

Review 10.  From discovery to licensure, the Adjuvant System story.

Authors:  Nathalie Garçon; Alberta Di Pasquale
Journal:  Hum Vaccin Immunother       Date:  2016-09-16       Impact factor: 3.452

View more
  1 in total

Review 1.  TLR2 as a Therapeutic Target in Bacterial Infection.

Authors:  Morgan E Simpson; William A Petri
Journal:  Trends Mol Med       Date:  2020-06-17       Impact factor: 11.951

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.